Welcome to INTERMACSTM!
The Interagency Registry for Mechanically Assisted Circulatory Support is a North American registry established in 2005 for patients who are receiving mechanical circulatory support device therapy to treat advanced heart failure. INTERMACSTM was established as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA), clinicians, scientists and industry representatives in conjunction with Dr. James K. Kirklin and the University of Alabama at Birmingham.
INTERMACSTM provides contemporary data to demonstrate the continued progress of outcomes, with additional insight into appropriate risk stratification and patient selection. Death, transplant, and explant are the major discrete endpoints recorded.
Complex endpoints that include the patient’s level of function and quality of life, critical to the evaluation of current MCSD therapy, for which improvements in both survival and function have been compelling. These indices are becoming increasingly important as the survival improves, and new devices will be compared for outcomes beyond survival.
INTERMACS EIGHTH ANNUAL MEETING, MAY 4-5, 2014, ARLINGTON, VIRGINIA
May 4, 2014 Data Collection Updates
Session 1: 4:30pm to 6:30pm (For centers that enter
adult subjects only)
Session 2: 7:00pm to 9:00pm (For centers that enter
pediatric subjects only or adult and pediatric subjects)
May 5, 2014 Scientific Sessions
7:30am to 3:15pm
Information and Registration
Please find attached an Information/Registration Form and a Preliminary Agenda for the INTERMACS 8th Annual Meeting.
Crowne Plaza Washington National Airport
1480 Crystal Drive
Arlington, VA 22201
Hotel accommodations can be made by calling 1-800-2CROWNE and requesting the ‘INTERMACS 8th Annual Meeting’ or go to the on-line link at
We look forward to seeing everyone in Arlington!
The INTERMACS Executive Committee has reviewed the CMS Decision Memo for Ventricular Assists Devices for Bridge-to-Transplant and Destination Therapy (CAG-00432R). We are excited to share with you the Executive Committee’s comments.
INTERMACS Comments Regarding the CMS Decision Memo
INTERMACS Reports for CMS
At the request of CMS, INTERMACS has produced two customized reports which are now available to the public.
Sponsored by The National Heart, Lung and Blood Institute (NHLI) and housed at the University of Alabama at Birmingham, INTERMACS launched June 2006 with 15 participating hospitals within the United States. The registry has quickly grown to include the majority of VAD centers in the U.S, is recognized as the Centers for Medicare and Medicaid Services (CMS) mandated registry for all U.S. centers implanting VADS for destination therapy and now has expanded to include all interested North American hospitals.
Currently 150 centers participate in INTERMACS.
This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract Number HHSN268201100025C.